Last update :
27/10/2020
Anticancer drug   Etoposide  
Injection
Oral solution
Stability in solutions Stability of mixtures Factors which affect stability Incompatibilities Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eposin Belgium, Colombia, Great Britain, Malaysia, Norway, Republic of South Africa, Sweden
Etocris Argentina, Chile, Peru
Etolon India
Etomedac Germany, Luxembourg
Etonolver Venezuela
Etoposide France, Greece, Netherlands
Etosid Egypt, India, Malaysia
Eunades Brazil
Exitop Finland, Germany, Sweden
Fytosid Egypt, India, Malaysia
Lastet Egypt, Hungary, Iran, Italy, Poland, Turkey, United Arab Emirates
Onkoposid Germany
Riboposid Germany
Sedol Peru
Toposin Netherlands
Tosuben Mexico
Vepesid Australia, Austria, Belgium, Canada, Colombia, Croatia, Denmark, Egypt, Finland, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Netherlands, Poland, Republic of South Africa, Saudi Arabia, Slovenia, Spain, Switzerland, Turkey, United States of America
Vepeside Morocco, Tunisia
Stability of mixtures   Injection   Stability of mixtures : Etoposide     
Container Solvent Concentration Compound Temperature Storage Length of time References
Glass Sodium chloride 0,9% 0,2 & 0,4 mg/ml
Injection   Etoposide   
Injection   Cisplatin 0,2 mg/ml
20,5°C-24°C
48 Hour
Protect from light 417
Level of evidence D
Glass Sodium chloride 0,9% 0,2 mg/ml
Injection   Etoposide   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Light 57
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,2 & 0,4 mg/ml
Injection   Etoposide   
Injection   Cisplatin 0,2 mg/ml
20,5°C-24°C
48 Hour
Protect from light 417
Level of evidence D
Polyvinyl chloride Glucose 5% 0,1 & 0,4 mg/ml
Injection   Etoposide   
Injection   Ondansetron hydrochloride 0,03 & 0,3 mg/ml
21°C-23°C
48 Hour
Light 184
Level of evidence C+
Polyvinyl chloride NaCl 0,45% Glucose 5% 0,4 mg/ml
Injection   Etoposide   
Injection   Cytarabine 0,26 mg/ml
Injection   Daunorubicin hydrochloride 0,03 mg/ml
20°C
72 Hour
Light 643
Level of evidence D
Polypropylene Glucose 5% 0,157 mg/ml
Injection   Etoposide   
Injection   Cytarabine 0,157 mg/ml
Injection   Daunorubicin hydrochloride 0,0157 mg/ml
25°C
48 Hour
With or without light 152
Joker
Polypropylene Glucose 5% 0,157 mg/ml
Injection   Etoposide   
Injection   Cytarabine 0,157 mg/ml
Injection   Daunorubicin hydrochloride 0,0157 mg/ml
4°C
48 Hour
Protect from light 152
Joker
Polyolefine Sodium chloride 0,9% 0,250 mg/ml
Injection   Etoposide   
Injection   Vincristine sulfate 0,002 mg/ml
Injection   Doxorubicin hydrochloride 0,050 mg/ml
23°C-25°C
72 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,125 mg/ml
Injection   Etoposide   
Injection   Doxorubicin hydrochloride 0,025 mg/ml
Injection   Vincristine sulfate 0,001 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,175 mg/ml
Injection   Etoposide   
Injection   Vincristine sulfate 0,0014 mg/ml
Injection   Doxorubicin hydrochloride 0,035 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,125 mg/ml
Injection   Etoposide   
Injection   Epirubicin hydrochloride 0,0375 mg/ml
Injection   Vindesine sulfate 0,002 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,175 mg/ml
Injection   Etoposide   
Injection   Vindesine sulfate 0,0028 mg/ml
Injection   Epirubicin hydrochloride 0,0525 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,250 mg/ml
Injection   Etoposide   
Injection   Epirubicin hydrochloride 0,075 mg/ml
Injection   Vindesine sulfate 0,004 mg/ml
25°C
24 Hour
Light 4352
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,200 mg/ml
Injection   Etoposide   
Injection   Doxorubicin hydrochloride 0,040 mg/ml
Injection   Vincristine sulfate 0,0016 mg/ml
31°C-33°C
72 Hour
With or without light 1033
Level of evidence A
Not specified NaCl 0,9% or Glucose 5% 0,2 mg/ml
Injection   Etoposide   
Injection   Topotecan 0,028 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
Not specified None 10 mg/ml
Injection   Etoposide   
Injection   Mitoxantrone dihydrochloride 1 mg/ml
25°C
22 Hour
Protect from light 1730
Level of evidence D
Not specified None 0,5 mg/ml
Injection   Etoposide   
Injection   Mitoxantrone dihydrochloride 0,05 mg/ml
25°C
22 Hour
Protect from light 1730
Level of evidence D

  Mentions Légales